-
Shock and OLE: Larimar (LRMR) provides update to ongoing long-term Open Label Study of nomlabofusp in Friedreich’s Ataxia
TL;DR Anyph-Fractious Reactions Larimar reported data from their ongoing OLE trial for nomlabofusp in Friedreich’s Ataxia (FA) this morning and it’s got investors itching. Overshadowing any results on efficacy were a reported 7 cases of anaphylaxis. A known risk and previously recognized adverse event, the frequency still comes as a surprise. This has resulted in… Continue reading
-
Lighting Up Larimar: How Nomlabofusp Could Rewire Friedreich’s Ataxia
Bottom Line Up Front: Friedreich’s Ataxia: A Disease of Lost Energy Before diving into Larimar, it’s important to understand the disease the team over there is fighting. FA is a rare, inherited, and relentlessly progressive neurodegenerative disorder. It’s caused by a specific genetic mutation called a repeat expansion — think of it as a sort… Continue reading
Complex science, clear takeaways